{"id":"NCT00399035","sponsor":"AstraZeneca","briefTitle":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","officialTitle":"A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2010-03","completion":"2016-08","firstPosted":"2006-11-14","resultsPosted":"2012-10-30","lastUpdate":"2016-12-28"},"enrollment":1254,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Cediranib","otherNames":["AZD2171","RECENTIN™"]},{"type":"DRUG","name":"FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)","otherNames":["Other Names:","5-FU","Drug: Leucovorin (in FOLFOX)","intravenous infusion","Drug: Oxaliplatin (in FOLFOX)","Eloxatin®"]},{"type":"DRUG","name":"XELOX (Capecitabine and Oxaliplatin)","otherNames":["Xeloda® + Eloxatin®"]},{"type":"DRUG","name":"Cediranib Placebo","otherNames":[]}],"arms":[{"label":"FOLFOX + placebo Cediranib","type":"PLACEBO_COMPARATOR"},{"label":"Xelox + placebo Cediranib","type":"PLACEBO_COMPARATOR"},{"label":"FOLFOX + Cediranib","type":"EXPERIMENTAL"},{"label":"XELOX + Cediranib","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal cancer.","primaryOutcome":{"measure":"Progression-free Survival","timeFrame":"RECIST assessed at baseline every 6 weeks through to week 24 and 12 week thereafter through to progression or data cut off date of 21/03/10 whichever was earliest.","effectByArm":[{"arm":"Cediranib 20 mg","deltaMin":8.6,"sd":null},{"arm":"Placebo","deltaMin":8.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":90,"countries":["Argentina","Australia","Brazil","Bulgaria","China","Czechia","Germany","Hungary","India","Philippines","Poland","South Korea","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["23510802"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=424&filename=CSR-D8480C00051.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":94,"n":214},"commonTop":["Diarrhoea","Nausea","Decreased Appetite","Vomiting","Fatigue"]}}